7530-27-0

Basic information

• Product Name: 4-BROMO-2-CHLORO-6-METHYLPHENOL
• Synonyms: 4-BROMO-2-CHLORO-6-METHYLPHENOL;4-BROMO-6-CHLORO-O-CRESOL;4-Bromo-2-chloro-6-methylphenol 97%;5-Bromo-3-chloro-2-hydroxytoluene;Phenol, 4-broMo-2-chloro-6-Methyl-;5-Bromo-3-chloro-2-hydroxytoluene, 4-Bromo-6-chloro-o-cresol;2-Chloro-4-bromo-6-methylphenol;4-Bromo-2-chloro-6-methylphenol97%
• CAS NO: 7530-27-0
• Molecular Formula: C₇H₆BrClO
• Molecular Weight: 221.48
• EINECS: 231-394-4
• Product Categories: Phenyls & Phenyl-Het
• Mol File: 7530-27-0.mol
• Article Data: 5

Chemical Properties

• Melting Point: 45 °C
• Boiling Point: 254 °C at 760 mmHg
• Flash Point: 110°C
• Appearance: /
• Density: 1.674 g/cm³
• Vapor Pressure: 0.0111mmHg at 25°C
• Refractive Index: 1.604
• Storage Temp.: Inert atmosphere,Room Temperature
• PKA: 8.28±0.23(Predicted)
• CAS DataBase Reference: 4-BROMO-2-CHLORO-6-METHYLPHENOL(CAS DataBase Reference)
• NIST Chemistry Reference: 4-BROMO-2-CHLORO-6-METHYLPHENOL(7530-27-0)
• EPA Substance Registry System: 4-BROMO-2-CHLORO-6-METHYLPHENOL(7530-27-0)

Safety Data

• Hazard Codes: Xi
• Statements: 20/21/22-36/37/38
• Safety Statements: 22-36/37/39-37/39-26
• Hazardous Substances Data: 7530-27-0(Hazardous Substances Data)

Usage

General Description

4-Bromo-2-chloro-6-methylphenol is a chemical compound that belongs to the class of phenolic compounds. It is a derivative of phenol with bromine, chlorine, and methyl substituents. This chemical has antimicrobial properties and is commonly used as a preservative in various products such as cosmetics, personal care products, and pharmaceuticals. It is also used as an intermediate in the production of pharmaceuticals and other organic compounds. 4-Bromo-2-chloro-6-methylphenol is a white to off-white crystalline powder with a slightly phenolic odor, and it is soluble in alcohol, ether, and chloroform. It is important to handle and store this chemical with proper safety measures due to its potential harmful effects on human health and the environment.

InChI:InChI=1/C7H6BrClO/c1-4-2-5(8)3-6(9)7(4)10/h2-3,10H,1H3

Upstream product

• 2362-12-1 4-Bromo-2-methylphenol 
• 87-64-9 2-chloro-6-methylphenol 

Downstream Products

• 1022249-15-5 2-(4-bromo-2-chloro-6-methylphenoxy)-4-chloro-7-(1-ethylpropyl)-1-methyl-1H-benzimidazole 

Relevant articles and documents

THIADIAZOLE MODULATORS OF S1P AND METHODS OF MAKING AND USING

The invention is directed to compounds of the formula: wherein each of the variables are defined herein, as well as methods of making and using the compounds as agonists of S1P1 and/or S1P5 for instance treating an autoimmune disease.

Treatment of estrogen-dependent diseases: Design, synthesis and profiling of a selective 17β-HSD1 inhibitor with sub-nanomolar IC50for a proof-of-principle study

Current endocrine therapeutics for the estrogen-dependent disease endometriosis often lead to considerable side-effects as they act by reducing estrogen action systemically. A more recent approach takes advantage of the fact that the weak estrogen estrone (E1) which is abundant in the plasma, is activated in the target cell to the highly estrogenic estradiol (E2) by 17β-hydroxysteroid dehydrogenase type 1 (17β-HSD1). 17β-HSD1 is overexpressed in endometriosis and thus a promising target for the treatment of this disease, with the prospect of less target-associated side-effects. Potent inhibitors from the class of bicyclic substituted hydroxyphenylmethanones with sulfonamide moiety recently described by us suffered from high molecular weight and low selectivity over 17βHSD2, the physiological adversary of 17β-HSD1. We describe the structural optimizations leading to the discovery of (5-(3,5-dichloro-4-methoxyphenyl)thiophen-2-yl)(2,6-difluoro-3-hydroxyphenyl)methanone 20, which displayed a sub-nanomolar IC50towards 17β-HSD1 as well as high selectivity over the type 2 enzyme, the estrogen receptors α and β and a range of hepatic CYP enzymes. The compound did neither show cellular toxicity, nor PXR activation nor mutagenicity in the AMES II assay. Additional favourable pharmacokinetic properties (rat) make 20 a suitable candidate for proof-of-principle studies using xenotransplanted immunodeficient rats.

A REGIOSPECIFIC SYNTHESIS OF CARBAZOLES VIA CONSECUTIVE PALLADIUM-CATALYZED CROSS-COUPLING AND ARYNE-MEDIATED CYCLIZATION

A regiospecific synthesis of carbazoles has been developed using palladium-catalyzed cross-coupling of N-(tert-butoxycarbonyl)-2-tributylstannylanilines with 2- or 3-bromochlorobenzene followed by aryne-mediated cyclization as the key reactions.The carbazole alkaloids, glycozolinine and glycozolidine, were synthesized using this procedure.